Abstract
Despite the extensive work on pathological mechanisms and some recent advances in the treatment of different hematological malignancies, leukemia continues to present a significant challenge being frequently considered as incurable disease. Therefore, the development of novel therapeutic agents with high efficacy and low toxicity is urgently needed to improve the overall survival rate of patients. In this comprehensive review article, the current knowledge about the anticancer activities of flavonoids as plant secondary polyphenolic metabolites in the most commonly used human established leukemia cell lines (HL-60, NB4, KG1a, U937, THP-1, K562, Jurkat, CCRF- CEM, MOLT-3, and MOLT-4) is compiled, revealing clear anti-proliferative, pro-apoptotic, cell cycle arresting, and differentiation inducing effects for certain compounds. Considering the low toxicity of these substances in normal blood cells, the presented data show a great potential of flavonoids to be developed into novel anti-leukemia agents applicable also in the malignant cells resistant to the current conventional chemotherapeutic drugs.
Keywords: Antiproliferation, Apoptosis, Cell cycle arrest, Cytotoxicity, Differentiation, Flavonoids, Leukemia, Human cell lines.
Graphical Abstract
Current Genomics
Title:Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids
Volume: 18 Issue: 1
Author(s): Katrin Sak and Hele Everaus
Affiliation:
Keywords: Antiproliferation, Apoptosis, Cell cycle arrest, Cytotoxicity, Differentiation, Flavonoids, Leukemia, Human cell lines.
Abstract: Despite the extensive work on pathological mechanisms and some recent advances in the treatment of different hematological malignancies, leukemia continues to present a significant challenge being frequently considered as incurable disease. Therefore, the development of novel therapeutic agents with high efficacy and low toxicity is urgently needed to improve the overall survival rate of patients. In this comprehensive review article, the current knowledge about the anticancer activities of flavonoids as plant secondary polyphenolic metabolites in the most commonly used human established leukemia cell lines (HL-60, NB4, KG1a, U937, THP-1, K562, Jurkat, CCRF- CEM, MOLT-3, and MOLT-4) is compiled, revealing clear anti-proliferative, pro-apoptotic, cell cycle arresting, and differentiation inducing effects for certain compounds. Considering the low toxicity of these substances in normal blood cells, the presented data show a great potential of flavonoids to be developed into novel anti-leukemia agents applicable also in the malignant cells resistant to the current conventional chemotherapeutic drugs.
Export Options
About this article
Cite this article as:
Sak Katrin and Everaus Hele, Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids, Current Genomics 2017; 18 (1) . https://dx.doi.org/10.2174/1389202917666160803165447
DOI https://dx.doi.org/10.2174/1389202917666160803165447 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry Magnetic Iron Oxide Nanoparticles for Tumor-Targeted Therapy
Current Cancer Drug Targets Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders
Current Topics in Medicinal Chemistry Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Malignancy Risk in Systemic Lupus: Recent Research and Ongoing Challenges
Current Rheumatology Reviews HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans
Infectious Disorders - Drug Targets Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts
Current Cancer Drug Targets Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma
Current Topics in Medicinal Chemistry Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Standardization of Procedures for the Preparation of <sup>177</sup>Lu- and <sup>90</sup>Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation
Current Radiopharmaceuticals Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design